Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Int J Gynecol Cancer ; 29(7): 1177-1181, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31302627

RESUMEN

INTRODUCTION: The National Comprehensive Cancer Network (NCCN) guidelines recommend intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients. The objective of this investigation was to determine the rate of intraperitoneal port placement in patients undergoing surgery for ovarian cancer in a national database maintained by the American College of Surgeons. METHOD: We identified ovarian cancer patients in the National Surgical Quality Improvement Program database from 2006 to 2012. Demographics, comorbidities, operative outcomes, and postoperative complications were abstracted. Descriptive analyses were conducted using Wilcoxon rank-sum and Chi square tests, and multivariate regression models were used to analyze pre-operative and post-operative variables associated with intraperitoneal port placement. RESULTS: We identified 2659 ovarian cancer patients who underwent primary surgical management. Of these patients, only 128 (4.8%) had an intraperitoneal port placed at the time of surgery. In multivariable analyses, intraperitoneal ports were associated with body mass index ≤25, disseminated cancer, later portion of the study period (2009-2012), and operative time >200 min. Intraperitoneal port placement was not associated with any difference in surgical site infection, wound disruption, major postoperative complication, readmission within 30 days, or death within 30 days. DISCUSSION: Recent investigation of practice at NCCN institutions between 2003 and 2012 found only 35% of eligible ovarian cancer patients received intraperitoneal chemotherapy. Using intraperitoneal port placement as a surrogate for intraperitoneal chemotherapy administration, our investigation suggests an even lower rate (4.8%) nationally.


Asunto(s)
Carcinoma Epitelial de Ovario/tratamiento farmacológico , Carcinoma Epitelial de Ovario/cirugía , Catéteres de Permanencia/estadística & datos numéricos , Sistemas de Liberación de Medicamentos/estadística & datos numéricos , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/cirugía , Anciano , Carcinoma Epitelial de Ovario/epidemiología , Carcinoma Epitelial de Ovario/patología , Estudios de Cohortes , Femenino , Humanos , Infusiones Parenterales , Persona de Mediana Edad , Análisis Multivariante , Estadificación de Neoplasias , Neoplasias Ováricas/epidemiología , Neoplasias Ováricas/patología , Peritoneo/cirugía , Estados Unidos/epidemiología
2.
Contraception ; 100(3): 234-240, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31152697

RESUMEN

OBJECTIVES: The objective of this study is to understand patient-, provider- and system-level factors associated with long-acting reversible contraception (LARC) use among women Veterans and with receipt of LARC methods within the Veterans Affairs (VA) system. STUDY DESIGN: We analyzed data from a national telephone-based survey of 2302 women ages 18-44 receiving primary care in VA. Multivariable regression was used to examine adjusted associations of participant-reported patient-, provider- and facility-level factors with LARC use and within-VA receipt of LARC among women Veterans. RESULTS: Among 987 women Veterans at risk of unintended pregnancy, 294 (30%) reported using LARC, 65% of whom had received their method within VA. Higher LARC use was observed among women who were multiparous vs. nulliparous [adjusted odds ratio (aOR)=1.52; 95% confidence interval (CI)=1.04-2.22] and did not desire future pregnancies (aOR=1.88; 95% CI=1.31-2.68). Although overall LARC uptake was not associated with any provider- or facility-level factors, receipt of these methods within VA was associated with receiving both general and gender-specific health care by a single provider (aOR=2.81; 95% CI=1.20-6.61) and with receiving care within a women's health clinic (aOR=2.54; 95% CI=1.17-5.50). CONCLUSIONS: While patient-level factors were more strongly correlated with use of LARC, provider- and system-level factors influence whether women received these methods within VA. IMPLICATIONS: This study of patient-, provider- and system-level correlates of LARC use in VA, the country's largest integrated healthcare system, highlights that women Veterans share similar patient-level factors associated with LARC use as the general population and that continuity with providers and comprehensive women's health services can facilitate LARC access.


Asunto(s)
Anticoncepción Reversible de Larga Duración/estadística & datos numéricos , Veteranos/estadística & datos numéricos , Salud de la Mujer , Adulto , Instituciones de Atención Ambulatoria , Estudios Transversales , Femenino , Humanos , Análisis Multivariante , Embarazo , Embarazo no Planeado , Análisis de Regresión , Encuestas y Cuestionarios , Estados Unidos , Servicios de Salud para Veteranos , Adulto Joven
3.
Rev Obstet Gynecol ; 5(2): 69-77, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22866185

RESUMEN

Puerperal infection remains a major cause of maternal morbidity and mortality. The primary risk factor is cesarean delivery, which increases the risk 5- to 20-fold. This article reviews in detail the risk of puerperal infection following cesarean delivery, both endometritis and surgical site infection, in both high- and low-risk populations. Strategies to prevent such infections are also discussed using a systematic evidence-based approach.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA